Inflammatory biomarkers in Alzheimer's disease plasma.
Journal article

Inflammatory biomarkers in Alzheimer's disease plasma.

  • Morgan AR Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
  • Touchard S Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
  • Leckey C Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
  • O'Hagan C Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK.
  • Nevado-Holgado AJ Department of Psychiatry, University of Oxford, Oxford, UK.
  • Barkhof F Max Planck Institute for Molecular Genetics, Berlin, Germany.
  • Bertram L Aix-Marseille University, APHM, Institute Neurosci System, Pharmacology, Marseille, France.
  • Blin O Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands.
  • Bos I Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany.
  • Dobricic V Department of Neurology, Hospital Network Antwerp (ZNA), Antwerp, Belgium; Reference Center for Biological Markers of Dementia, Institute Born-Bunge, Antwerp, Belgium.
  • Engelborghs S University of Geneva, Geneva, Switzerland; IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
  • Frisoni G Department of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit, University of Heidelberg, Mannheim, Germany.
  • Frölich L Department of Neurosciences, Laboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.
  • Gabel S Division of Clinical Geriatrics, Department of Neurobiology, Caring Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
  • Johannsen P University of Gothenburg, Institute of Neuroscience and Physiology, Gothenburg, Sweden.
  • Kettunen P Department of Old Age Psychiatry & Psychotic Disorders, Medical University of Lodz, Lodz, Poland.
  • Kłoszewska I UCL Institutes of Neurology and Healthcare Engineering, University College London, London, UK; School of Public Health, Imperial College London, London, UK.
  • Legido-Quigley C Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Lleó A CITA-Alzheimer Foundation, San Sebastian, Spain.
  • Martinez-Lage P Department of Medicine, Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy.
  • Mecocci P Department of Neurosciences, Laboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.
  • Meersmans K Barcelona Beta Brain Research Center, Unversitat Pompeu Fabra, Barcelona, Spain.
  • Molinuevo JL Department of Psychiatry, Old Age Psychiatry, Lausanne University Hospital, Lausanne, Switzerland.
  • Peyratout G Hopitaux Universitaires Geneve and Universite de Geneve, Geneva, Switzerland.
  • Popp J Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK.
  • Richardson J Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Sala I Alzheimer Center, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, the Netherlands.
  • Scheltens P Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
  • Streffer J Institute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland.
  • Soininen H Center for Research and Advanced Therapies. CITA-Alzheimer Foundation, San Sebastian, Spain.
  • Tainta-Cuezva M University Hospital Leuven, Leuven, Belgium.
  • Teunissen C 1st Department of Neurology, AHEPA University Hospital, Makedonia, Thessaloniki, Greece.
  • Tsolaki M Department of Clinical Chemistry, Neurochemistry lab, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • Vandenberghe R Department of Psychiatry & Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.
  • Visser PJ Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands.
  • Vos S NVS-Department, Section of Clinical Geriatrics, Karolinska Institutet, Huddinge, Sweden.
  • Wahlund LO Section for Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden.
  • Wallin A Department of Psychiatry, University of Oxford, Oxford, UK.
  • Westwood S Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Mölndal, Sweden; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; UK Dementia Research Institute, London, UK.
  • Zetterberg H Department of Psychiatry, University of Oxford, Oxford, UK.
  • Lovestone S Systems Immunity Research Institute and UK Dementia Research Institute Cardiff, School of Medicine, Cardiff University, Cardiff, UK. Electronic address: morganbp@cardiff.ac.uk.
  • Morgan BP
Show more…
  • 2019-05-04
Published in:
  • Alzheimer's & dementia : the journal of the Alzheimer's Association. - 2019
English INTRODUCTION
Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers.


METHODS
A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed.


RESULTS
Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71).


DISCUSSION
Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.
Language
  • English
Open access status
hybrid
Identifiers
Persistent URL
https://sonar.ch/global/documents/279594
Statistics

Document views: 60 File downloads: